Anti sfrp2

The following antibodies were used in the study: anti‐SFRP2 (Santa Cruz, sc‐365,524, 1:300), anti‐THBS2 (Abcam, ab84469, 1:500), anti‐HSP90 (ABclonal, A5027, 1:2000) and anti‐GAPDH (ZSGB‐BIO, TA‐08, 1:2000). Secondary antibodies (Jackson Immuno Research Laboratories, West Grove, PA, USA) were diluted 1:4000 using 5% skim milk in Tris‐buffered saline.

Western blot analysis was performed using anti–ROCK-2 (1:500; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti–β-catenin (1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-RUNX2 (1:500; Abcam), anti–p-SAPK/JNK (1:1000; Cell Signaling Technology), anti-SAPK/JNK (1:1000; Cell Signaling Technology), anti-SMA (1:500; Santa Cruz), anti-Wnt5a (1:1000; Abcam), anti-Wnt3a (1000; Millipore), anti-sFRP5 (1:2000; Thermo Fisher), anti-sFRP4 (1:500; Santa Cruz), anti-sFRP3 (1:500; Santa Cruz), anti-sFRP2 (1:500; Santa Cruz), anti-sFRP1 (1:500; Santa Cruz), and anti-GAPDH (1:5000; Flarebio, College Park, MD, USA) antibodies. Blots were immunolabeled using horseradish peroxidase-conjugated secondary antibody and incubated with chemiluminescent substrate (Pierce ECL Plus Western Blotting Substrate; Thermo). The Western blots were quantified using ImageJ software (National Institutes of Health).